Int'l : +1-503-894-6022 | Toll Free : +1-800-792-5285 | help@alliedmarketresearch.com
A00710 | Pages: 114 | Charts: 30 | Tables: 77 |
Asia-Pacific IVF Service Market Statistics, 2031
The Asia-Pacific IVF service market size was valued at $9373.2 Million in 2021 and is projected to reach $46216.8 Million by 2031, registering a CAGR of 17.1% from 2022 to 2031. Rise in disposable income has increased the adoption of IVF techniques. Couples who usually opt for IVF treatment belong to the middle-aged group with stable financial conditions. Higher success rate of IVF treatment attracts infertile couples to undergo the procedure, despite high-cost cycle and medications are driving the IVF market in Asia-Pacific.
In vitro fertilization (IVF) process involves fertilization of egg cells by sperm outside the woman’s body and then implanting it in the uterus. It is a type of assisted reproductive technology (ART) based treatment, which is used to treat fertility or genetic problems to assist with conception of child. It is the process of fertilization, which includes extraction of eggs, retrieval of sperm cells, and then manually combining them in laboratory settings to form an embryo. The embryo(s) is then transferred to uterus for further gestation.
In vitro fertilization (IVF) is a type of assisted reproductive technology in which the ovum is artificially fertilized in laboratory settings and then implanted into uterus. IVF is one of the widely used treatments, which assist people with infertility problems including couples, single mothers, and the LGBT community
“The Asia-Pacific IVF service market was slightly negative during the lockdown period owing to a decrease in demand for IVF service. Decrease in the number of consultations for infertility, and sharp cut in income during COVID-19 is anticipated to hamper the market growth”
Historical overview
The market was analyzed qualitatively and quantitatively from 2021-2031. The Asia-Pacific IVF treatment market grew at a CAGR of around 17.1% during 2021-2031. Most of the growth during this period was derived from the China owing to the rise in the number of key players who manufactures IVF service product, rising disposable incomes, as well as well-established presence of domestic companies in the region
Market Dynamics
Growth of the global Asia-Pacific IVF service market is majorly driven by rise in acceptance of IVF procedure, increase in the IVF success rate and rise in awareness among population regarding IVF procedure. The success rate of IVF is on rise with subsequent advancements in technology. New and advanced techniques used in IVF such as pre-implantation genetic diagnosis (PGD), Intracytoplasmic sperm injection (ICSI) and in vitro maturation (IVM) have helped increase the success rates of pregnancy. For instance, according to Assisted Reproductive Technology in Australia and New Zealand (ANZARD) report in September 2021, stated that 19% to 23% increase live birth rate per cycle in women aged 35-39, represented a 20% relative increase in success rates and in those aged 40-44, the live birth rate increased to 10%, representing a 27% increase in success rates over the last 10 years. Thus, this has positively impacted the growth of the Asia-Pacific IVF service market.
As per the data published by National Bureau of Statistics of China, the per capita disposable income of China, in 2021, was increased up to $12,554.646 as compared to previous year income which was $10,409.993 in December 2020. Moreover, governments and private sector authorities provide favorable reimbursement schemes for infertility treatments. For instance, the Australian Government provides reimbursements for IVF cycle that cover unlimited access of IVF treatment for patients.
Increase in infertility rates is one of the major factors that drives the growth of the Asia-Pacific IVF services market. Lifestyle habits such as smoking & excessive alcohol use, increase in prevalence of obesity, excessive emotional stress, PCOS, and fallopian tube obstruction are the major factors that affect the reproductive health of an individual.
Rise in infertility rates is not only due to lifestyle changes but also due to increase in incidences of various diseases such as sexually transmitted diseases and fertility-related diseases. Thus, surge in infertility cases is anticipated to drive the growth of the Asia-Pacific IVF services market. In addition, as per Central Intelligence agency, the fertility rate is in general declining and is expected to continue for the next 50 years. As per their data, the fertility rate (2020 est.) in India, China, Japan, Australia, New Zealand, South Korea, Thailand, Singapore, Malaysia, Indonesia, the Philippines, and Vietnam are 2.35, 1.6, 1.43, 1.74, 1.87, 1.29, 1.54, 0.87, 2.43, 2.04, 2.92, and 1.77.
Fertility tourism provides steady prospects for the growth of the Asia-Pacific IVF service market. Fertility tourism not only helps economy of developing countries but also facilitates benefits to patients, as prices are lower compared to developed countries. The cost of one IVF cycle in North America is approximately $15,000 to $30,000, whereas in Thailand, the treatment costs roughly $3,587.
In addition, according to the report of CNY fertility in 2021, the IVF treatment in India can range from $1,317 to $4,610 per cycle and medications may cost from $800 to $1000. In addition, higher age limit and relaxed regulations on fertility coupled with lower costs is anticipated to drive the IVF services in India. Furthermore, donor egg IVF services are not available in some countries such as Germany and Italy, due to which patients prefer to travel to Asia, where donor egg IVF is allowed. Hence, patients opt for lower cost fertility destinations; thereby, creating newer opportunities for the growth of the IVF services market in Asia-Pacific.
However, complications associated with IVF treatment such as multiple pregnancies and birth defects limit the adoption of IVF services. Success rates of IVF depends on the number of embryos transferred, which can lead to multiple pregnancies. The complications that arise from multiple pregnancies include high blood pressure and complications related to delivery. Furthermore, due to multiple pregnancies, a child can incur several health-related problems such as low birth weight and premature birth. In addition, one of the potential risks associated with IVF treatment is ectopic pregnancy, where the embryo gets implanted outside the woman’s womb, resulting in life threatening situations. For instance, as per the article published by National Library of Medicine in 2020, approximately 0.8% to 8.6% patients undergoing IVF treatment may suffer from ectopic pregnancies. These factors limit the adoption of IVF procedures; thereby, hindering the market growth.
COVID-19 Impact on the Asia-Pacific IVF service Market
The COVID-19 outbreak is anticipated to have a negative impact on the growth of the global Asia-Pacific IVF service market. Many countries across the globe adopted nationwide lockdowns, which directly impacted the key driver fertility tourism, owing to flight cancellations, travel bans & quarantines, restriction of all indoor/outdoor events, emergency declaration. A huge number of clinics and hospitals were restructured to increase the hospital capacity for the patient diagnosed with COVID-19. Non-urgent visits of people were discouraged in fertility clinics and elective fertility treatments were being postponed owing to direct contact of physicians to people who want to get IVF treatment. Subsequently, these factors led to cancellation of many scheduled IVF procedures and anticipated to hinder the growth of the Asia-Pacific IVF service market during the pandemic.
Segmental Overview
The Asia-Pacific IVF service market is segmented based on cycle type, end user and country. Based on type the market is segmented into fresh IVF cycle(non-donor), thawed IVF cycle (non- donor) and donor eggs IVF cycle. Based on end user, market is divided into fertility clinics, hospitals, surgical centers and clinical research institutes. Region-wise, the market is analyzed across Asia-Pacific.
By Cycle Type: Based on cycle type, the market is segmented into fresh IVF cycle (non-donor), thawed IVF cycle (non-donor) and donor eggs IVF cycle. The fresh IVF cycles (non-donor) segment dominated the market in 2021 and is expected to continue this trend during the forecast period, owing to rise in prevalence of infertility among female population and increase in the number of product launch for IVF technology.
By end user: Based on end user, the market is divided into fertility centers, hospital, surgical centers and clinical research institutes. The fertility clinics segment dominated the market in 2021 and is expected to continue this trend during the forecast period, owing to increase in the number of fertility clinics and rise in the expenditure by government to develop healthcare infrastructure.
Delayed pregnancy trends have steadily increased in the past few years. In older women (more than 40 years), eggs produced by the reproductive system are immature for the process of fertilization. This results in the risk of genetic disorders in the egg. Furthermore, due changes in lifestyles, such as the increased prevalence of obesity and stress, lack of exercise, improper eating habits, lack of nutrition has increased the cases of premature menopause result in reduced healthy egg production and increased chances of miscarriage. For instance, according to the article by Obstetrics and Gynecology in September 2021, stated that prevalence of premature menopause in Indian women was 3.7%, out of which 2.1% of women had experienced natural premature menopause. Thus, rise in trend of delayed pregnancy in women is anticipated to drive the growth of the Asia-Pacific IVF services market.
The trends in the IVF services market keep changing with the growth in need for efficient technologies that save time, cost, and efficiency of the procedure resulting in better success rates. Specialty IVF clinics offer various types of IVF services and are equipped with technologically advanced IVF devices. Furthermore, as per ICMR (Indian Council of Medical Research), in 2021, there were 508 registered assisted reproductive technology (ART) clinics under the National Registry of ART clinics and Banks in India. Therefore, rise in number of fertility clinics is anticipated to promote the growth of the IVF services market in the future.
[CYCLETYPEGRAPH]
Competition Analysis
Some of the major companies that operate in the Asia-Pacific IVF service market include Bourn Hall Fertility Center, Southend Fertility and IVF, Morpheus Life Sciences Pvt. Ltd., Bloom Fertility Center, Manipal Fertility, Cloudnine Fertility, and Chennai Fertility Center.
Some examples of product launch in the market
In March 2020, Gurugram Hospital, launched a Specialized Infertility Program and Awareness Campaign to make infertile couples aware about medical advancement by sharing IVF success stories with the audience on how the availability of modern and advanced technology is helping couples embracing parenthood.
[ENDUSERGRAPH]
In 2020, Fujifilm Irvine Scientific launched a vitrification media solution named Vit Kit-NX, it is a media aimed to safeguard embryos and achieve high survival rates. Thus, rise in number of product approval, product launch and partnership for the IVF service is anticipated to drive the market growth.
Partnership in the market
In 2020, Morula IVF Jakarta, a chain of fertility clinics, established partnerships with 14 Women and Children Hospitals, categorized as Morula Satellite Clinics. The company plans to expand its strategic partnerships by introducing its satellite programs into 300 Morula Satellite Clinics within the next five years. Moreover, the company has expanded its number of partnerships by signing 60 partnerships in 2021.
[COUNTRYGRAPH]
Key Benefits for Stakeholders
Key Market Segments
CHAPTER 1:INTRODUCTION
1.1.Report description
1.2.Key benefits for stakeholders
1.3.Key market segments
1.4.Research methodology
1.4.1.Secondary research
1.4.2.Primary research
1.4.3.Analyst tools and models
CHAPTER 2:EXECUTIVE SUMMARY
2.1.Key findings of the study
2.2.CXO perspective
CHAPTER 3:MARKET LANDSCAPE
3.1.Market definition and scope
3.2.Porter’s five forces analysis
3.3.Market dynamics
3.3.1.Drivers
3.3.1.1.Increase in IVF success rates
3.3.1.2.Surge in disposable income
3.3.1.3.Increase in infertility rates
3.3.1.4.Delayed pregnancies in women
3.3.2.Restraint
3.3.2.1.Complications associated with IVF treatment
3.3.3.Opportunities
3.3.3.1.Increase in number of fertility clinics
3.3.3.2.Growth opportunities in the region
3.3.3.3.Increase in demand for fertility tourism
3.4.Impact analysis
3.5.Impact analysis of COVID-19 on the Asia-Pacific IVF service market
CHAPTER 4:IVF SERVICE MARKET, BY CYCLE TYPE
4.1.Overview
4.1.1.Market size and forecast
4.2.Fresh IVF Cycle (Non-Donor)
4.2.1.Key market trends, growth factors, and opportunities
4.2.2.Market analysis, by country
4.3.Thawed IVF Cycle (Non-Donor)
4.3.1.Key market trends, growth factors, and opportunities
4.3.2.Market analysis, by country
4.4.Donor Egg IVF Cycle
4.4.1.Key market trends, growth factors, and opportunities
4.4.2.Market analysis, by country
CHAPTER 5:IVF SERVICE MARKET, BY END USER
5.1.Overview
5.1.1.Market size and forecast
5.2.Fertility Clinics
5.2.1.Key market trends, growth factors, and opportunities
5.2.2.Market analysis, by country
5.3.Hospitals
5.3.1.Key market trends, growth factors, and opportunities
5.3.2.Market analysis, by country
5.4.Surgical centers
5.4.1.Key market trends, growth factors, and opportunities
5.4.2.Market analysis, by country
5.5.Clinical research institutes
5.5.1.Key market trends, growth factors, and opportunities
5.5.2.Market analysis, by country
CHAPTER 6:ASIA-PACIFIC IVF SERVICE MARKET, BY REGION
6.1.Overview
6.2.Asia Pacific
6.2.1.Key market trends, growth factors, and opportunities
6.2.2.Asia-Pacific IVF service market, by cycle type
6.2.3.Asia-Pacific IVF service market, by end user
6.2.4.Market size and forecast, by country
6.2.4.1.Japan
6.2.4.1.1.Japan IVF services market, by cycle type
6.2.4.1.2.Japan IVF Services Market, by end user
6.2.4.2.India
6.2.4.2.1.India IVF services market, by cycle type
6.2.4.2.2.India IVF Services Market, by end user
6.2.4.3.China
6.2.4.3.1.China IVF services market, by cycle type
6.2.4.3.2.China IVF Services Market, by end user
6.2.4.4.Australia
6.2.4.4.1.Australia IVF services market, by cycle type
6.2.4.4.2.Australia IVF Services Market, by end user
6.2.4.5.New Zealand
6.2.4.5.1.New Zealand IVF services market, by cycle type
6.2.4.5.2.New Zealand IVF Services Market, by end user
6.2.4.6.South Korea
6.2.4.6.1.South Korea IVF services market, by cycle type
6.2.4.6.2.South Korea IVF Services Market, by end user
6.2.4.7.Thailand
6.2.4.7.1.Thailand IVF services market, by cycle type
6.2.4.7.2.Thailand IVF Services Market, by end user
6.2.4.8.Singapore
6.2.4.8.1.Singapore IVF services market, by cycle type
6.2.4.8.2.Singapore IVF Services Market, by end user
6.2.4.9.Malaysia
6.2.4.9.1.Malaysia IVF services market, by cycle type
6.2.4.9.2.Malaysia IVF Services Market, by end user
6.2.4.10.Indonesia
6.2.4.10.1.Indonesia IVF services market, by cycle type
6.2.4.10.2.Indonesia IVF Services Market, by end user
6.2.4.11.Philippines
6.2.4.11.1.Philippines IVF services market, by cycle type
6.2.4.11.2.Philippines IVF Services Market, by end user
6.2.4.12.Vietnam
6.2.4.12.1.Vietnam IVF services market, by cycle type
6.2.4.12.2.Vietnam IVF Services Market, by end user
6.2.4.13.Myanmar
6.2.4.13.1.Myanmar IVF services market, by cycle type
6.2.4.13.2.Myanmar IVF Services Market, by end user
6.2.4.14.Rest of Asia-Pacific
6.2.4.14.1.Rest of Asia-Pacific IVF services market, by cycle type
6.2.4.14.2.Rest of Asia-Pacific IVF Services Market, by end user
CHAPTER 7:COMPETITION LANDSCAPE
7.1.Product mapping
7.2.Competitive dashboard
7.3.Competitive heat map
7.4.Top Player Positioning 2022
CHAPTER 8:COMPANY PROFILES
8.1.APOLLO HOSPITALS
8.1.1.Company overview
8.1.2.Key Executive
8.1.3.Company snapshot
8.1.4.Operating business segments
8.1.5.Product portfolio
8.1.6.Business performance
8.2.GENEA LIMITED
8.2.1.Company overview
8.2.2.Key Executive
8.2.3.Company snapshot
8.2.4.Operating business segments
8.2.5.Product portfolio
8.3.BLOOM LIFE HOSPITAL
8.3.1.Company overview
8.3.2.Key Executive
8.3.3.Company snapshot
8.3.4.Operating business segments
8.3.5.Product portfolio
8.4.DAMAI SERVICE HOSPITAL
8.4.1.Company overview
8.4.2.Key Executive
8.4.3.Company snapshot
8.4.4.Operating business segments
8.4.5.Product portfolio
8.5.RAFFLE MEDICAL GROUP
8.5.1.Company overview
8.5.2.Key Executive
8.5.3.Company snapshot
8.5.4.Operating business segments
8.5.5.Product portfolio
8.5.6.Business performance
8.6.FERTILITY ASSOCIATES LIMITED
8.6.1.Company overview
8.6.2.Key Executive
8.6.3.Company snapshot
8.6.4.Operating business segments
8.6.5.Product portfolio
8.7.FLINDERS FERTILITY
8.7.1.Company overview
8.7.2.Key Executive
8.7.3.Company snapshot
8.7.4.Operating business segments
8.7.5.Product portfolio
8.8.MONASH IVF
8.8.1.Company overview
8.8.2.Key Executive
8.8.3.Company snapshot
8.8.4.Operating business segments
8.8.5.Product portfolio
8.8.6.Business performance
8.9.ST LUKE’S MEDICAL CENTRE
8.9.1.Company overview
8.9.2.Key Executive
8.9.3.Company snapshot
8.9.4.Operating business segments
8.9.5.Product portfolio
8.10.VIRTUS HEALTH
8.10.1.Company overview
8.10.2.Key Executive
8.10.3.Company snapshot
8.10.4.Operating business segments
8.10.5.Product portfolio
8.10.6.Business performance
LIST OF TABLES
TABLE 01.IVF SERVICE MARKET, BY CYCLE TYPE, 2021–2031 ($MILLION)
TABLE 02.IVF SERVICE MARKET, BY END USER, 2021–2031 ($MILLION)
TABLE 03.ASIA-PACIFIC IVF SERVICE MARKET, BY CYCLE TYPE, 2021–2031 ($MILLION)
TABLE 04.ASIA-PACIFIC IVF SERVICE MARKET, BY END USER, 2021–2031 ($MILLION)
TABLE 05.ASIA-PACIFIC IVF SERVICE MARKET, BY COUNTRY, 2021–2031 ($MILLION)
TABLE 06.JAPAN IVF SERVICES MARKET, BY CYCLE TYPE, 2021–2031 ($MILLION)
TABLE 07.JAPAN IVF SERVICES MARKET, BY USER, 2021–2031 ($MILLION)
TABLE 08.INDIA IVF SERVICES MARKET, BY CYCLE TYPE, 2021–2031 ($MILLION)
TABLE 09.INDIA IVF SERVICES MARKET, BY USER, 2021–2031 ($MILLION)
TABLE 10.CHINA IVF SERVICES MARKET, BY CYCLE TYPE, 2021–2031 ($MILLION)
TABLE 11.CHINA IVF SERVICES MARKET, BY USER, 2021–2031 ($MILLION)
TABLE 12.AUSTRALIA IVF SERVICES MARKET, BY CYCLE TYPE, 2021–2031 ($MILLION)
TABLE 13.AUSTRALIA SERVICES MARKET, BY USER, 2021–2031 ($MILLION)
TABLE 14.NEW ZEALAND IVF SERVICES MARKET, BY CYCLE TYPE, 2021–2031 ($MILLION)
TABLE 15.NEW ZEALAND IVF SERVICES MARKET, BY USER, 2021–2031 ($MILLION)
TABLE 16.SOUTH KOREA IVF SERVICES MARKET, BY CYCLE TYPE, 2021–2031 ($MILLION)
TABLE 17.SOUTH KOREA IVF SERVICES MARKET, BY USER, 2021–2031 ($MILLION)
TABLE 18.THAILAND IVF SERVICES MARKET, BY CYCLE TYPE, 2021–2031 ($MILLION)
TABLE 19.THAILAND IVF SERVICES MARKET, BY USER, 2021–2031 ($MILLION)
TABLE 20.SINGAPORE IVF SERVICES MARKET, BY CYCLE TYPE, 2021–2031 ($MILLION)
TABLE 21.SINGAPORE IVF SERVICES MARKET, BY USER, 2021–2031 ($MILLION)
TABLE 22.MALAYSIA IVF SERVICES MARKET, BY CYCLE TYPE, 2021–2031 ($MILLION)
TABLE 23.MALAYSIA IVF SERVICES MARKET, BY USER, 2021–2031 ($MILLION)
TABLE 24.INDONESIA IVF SERVICES MARKET, BY CYCLE TYPE, 2021–2031 ($MILLION)
TABLE 25.INDONESIA IVF SERVICES MARKET, BY USER, 2021–2031 ($MILLION)
TABLE 26.PHILIPPINES IVF SERVICES MARKET, BY CYCLE TYPE, 2021–2031 ($MILLION)
TABLE 27.PHILIPPINES IVF SERVICES MARKET, BY USER, 2021–2031 ($MILLION)
TABLE 28.VIETNAM IVF SERVICES MARKET, BY CYCLE TYPE, 2021–2031 ($MILLION)
TABLE 29.VIETNAM IVF SERVICES MARKET, BY USER, 2021–2031 ($MILLION)
TABLE 30.MYANMAR IVF SERVICES MARKET, BY CYCLE TYPE, 2021–2031 ($MILLION)
TABLE 31.MYANMAR IVF SERVICES MARKET, BY USER, 2021–2031 ($MILLION)
TABLE 32.REST OF ASIA-PACIFIC IVF SERVICES MARKET, BY CYCLE TYPE, 2021–2031 ($MILLION)
TABLE 33.REST OF ASIA-PACIFIC IVF SERVICES MARKET, BY USER, 2021–2031 ($MILLION)
TABLE 34.APOLLO HOSPITALS: KEY EXECUTIVE
TABLE 35.APOLLO HOSPITALS: COMPANY SNAPSHOT
TABLE 36.APOLLO HOSPITALS: OPERATING SEGMENT
TABLE 37.APOLLO HOSPITALS: PRODUCT PORTFOLIO
TABLE 38.APOLLO HOSPITALS: NET SALES, 2019–2021
TABLE 39.GENEA LIMITED: KEY EXECUTIVE
TABLE 40.GENEA LIMITED: COMPANY SNAPSHOT
TABLE 41.GENEA LIMITED: OPERATING SEGMENT
TABLE 42.GENEA LIMITED: PRODUCT PORTFOLIO
TABLE 43.BLOOM LIFE HOSPITAL: KEY EXECUTIVE
TABLE 44.BLOOM LIFE HOSPITAL: COMPANY SNAPSHOT
TABLE 45.BLOOM LIFE HOSPITAL: OERATING SEGMENT
TABLE 46.BLOOM LIFE HOSPITAL: PRODUCT PORTFOLIO
TABLE 47.DAMAI SERVICE HOSPITAL: KEY EXECUTIVE
TABLE 48.DAMAI SERVICE HOSPITAL: COMPANY SNAPSHOT
TABLE 49.DAMAI SERVICE HOSPITAL: OPERATING SEGMENT
TABLE 50.DAMAI SERVICE HOSPITAL: PRODUCT PORTFOLIO
TABLE 51.RAFFLE MEDICAL GROUP: KEY EXECUTIVE
TABLE 52.RAFFLE MEDICAL GROUP: COMPANY SNAPSHOT
TABLE 53.RAFFLE MEDICAL GROUP: OPERATING SEGMENT
TABLE 54.RAFFLE MEDICAL GROUP: PRODUCT PORTFOLIO
TABLE 55.RAFFLE MEDICAL GROUP: NET SALES, 2019–2021
TABLE 56.FERTILITY ASSOCIATES LIMITED: KEY EXECUTIVE
TABLE 57.FERTILITY ASSOCIATES LIMITED: COMPANY SNAPSHOT
TABLE 58.FERTILITY ASSOCIATES LIMITED: OPERATING SEGMENT
TABLE 59.FERTILITY ASSOCIATES LIMITED: PRODUCT PORTFOLIO
TABLE 60.FLINDERS FERTILITY: KEY EXECUTIVE
TABLE 61.FLINDERS FERTILITY: COMPANY SNAPSHOT
TABLE 62.FLINDERS FERTILITY: OPERATING SEGMENT
TABLE 63.FLINDERS FERTILITY: PRODUCT PORTFOLIO
TABLE 64.MONASH IVF GROUP LIMITED: KEY EXECUTIVE
TABLE 65.MONASH IVF GROUP LIMITED: COMPANY SNAPSHOT
TABLE 66.MONASH IVF GROUP LIMITED: OPERATING SEGMENT
TABLE 67.MONASH IVF GROUP LIMITED: PRODUCT PORTFOLIO
TABLE 68.MONASH IVF GROUP LIMITED: NET SALES, 2019–2021
TABLE 69.ST. LUKE’S MEDICAL CENTER: KEY EXECUTIVE
TABLE 70.ST. LUKE’S MEDICAL CENTER: COMPANY SNAPSHOT
TABLE 71.ST. LUKE’S MEDICAL CENTER: OPERATING SEGMENT
TABLE 72.ST. LUKE’S MEDICAL CENTER: PRODUCT PORTFOLIO
TABLE 73.VIRTUS HEALTH: KEY EXECUTIVE
TABLE 74.VIRTUS HEALTH: COMPANY SNAPSHOT
TABLE 75.VIRTUS HEALTH: OPERATING SEGMENT
TABLE 76.VIRTUS HEALTH: PRODUCT PORTFOLIO
TABLE 77.VIRTUS HEALTH: NET SALES, 2019–2021
LIST OF FIGURES
FIGURE 01.EXECUTIVE SUMMARY
FIGURE 02.ASIA-PACIFIC IVF SERVICE MARKET SEGMENTATION
FIGURE 03.MODERATE BARGAINING POWER OF SUPPLIERS
FIGURE 04.MODERATE BARGAINING POWER OF BUYERS
FIGURE 05.MODERATE THREAT OF SUBSTITUTES
FIGURE 06.HIGH THREAT OF NEW ENTRANTS
FIGURE 07.MODERATE INTENSITY OF RIVALRY
FIGURE 08.IMPACT ANALYSIS
FIGURE 09.IVF SERVICE MARKET, BY CYCLE TYPE, 2021–2031 (%)
FIGURE 10.COMPARATIVE ANALYSIS OF IVF SERVICE MARKET FOR FRESH IVF CYCLE (NON-DONOR), BY COUNTRY, 2021–2031 (%)
FIGURE 11.COMPARATIVE ANALYSIS OF IVF SERVICE MARKET FOR THAWED IVF CYCLE (NON-DONOR), BY COUNTRY, 2021–2031 (%)
FIGURE 12.COMPARATIVE ANALYSIS OF IVF SERVICE MARKET FOR DONOR EGG IVF CYCLE, BY COUNTRY, 2021–2031 (%)
FIGURE 13.IVF SERVICE MARKET, BY END USER, 2021–2031 (%)
FIGURE 14.COMPARATIVE ANALYSIS OF IVF SERVICE MARKET FOR FERTILITY CLINICS, BY COUNTRY, 2021–2031 (%)
FIGURE 15.COMPARATIVE ANALYSIS OF IVF SERVICE MARKET FOR HOSPITALS, BY COUNTRY, 2021–2031 (%)
FIGURE 16.COMPARATIVE ANALYSIS OF IVF SERVICE MARKET FOR SURGICAL CENTERS, BY COUNTRY, 2021–2031 (%)
FIGURE 17.COMPARATIVE ANALYSIS OF IVF SERVICE MARKET FOR CLINICAL RESEARCH INSTITUTES, BY COUNTRY, 2021–2031 (%)
FIGURE 18.PRODUCT MAPPING OF TOP 10 KEY PLAYERS
FIGURE 19.COMPETITIVE DASHBOARD OF TOP 10 KEY PLAYERS
FIGURE 20.COMPETITIVE HEATMAP OF TOP 10 KEY PLAYERS
FIGURE 21.TOP PLAYER POSITIONING 2022
FIGURE 22.APOLLO HOSPITALS: NET SALES, 2019–2021 ($MILLION)
FIGURE 23.APOLLO HOSPITALS: REVENUE SHARE BY SEGMENT, 2021 (%)
FIGURE 24.RAFFLE MEDICAL GROUP: NET SALES, 2019–2021 ($MILLION)
FIGURE 25.RAFFLE MEDICAL GROUP: REVENUE SHARE BY SEGMENT, 2021 (%)
FIGURE 26.RAFFLE MEDICAL GROUP: REVENUE SHARE BY REGION, 2021 (%)
FIGURE 27.MONASH IVF GROUP LIMITED: NET SALES, 2019–2021 ($MILLION)
FIGURE 28.MONASH IVF GROUP LIMITED: REVENUE SHARE BY SEGMENT, 2021 (%)
FIGURE 29.VIRTUS HEALTH: NET SALES, 2019–2021 ($MILLION)
FIGURE 30.VIRTUS HEALTH: REVENUE SHARE BY SEGMENT, 2021 (%)